Protein lysine methyltransferases constitute a large family of epigenetic writers which catalyse the transfer of a methyl group from the cofactor S-adenosyl-L-methionine to histone and non-histone specific substrates. Alterations in the expression and activity of these proteins have been linked to the insurgence and progress of several diseases, including cancer, neurological disorders, and growing defects, hence they represent interesting targets for new therapeutical approaches. Over the past two decades, the identification of modulators of lysine methyltransferases has increased tremendously, clarifying the role of these proteins in different physio-pathological states. The aim of this review is to furnish an updated outlook about the protein lysine methyltransferases disclosed modulators, reporting their potency, the mechanism of action and their eventual use in clinical and preclinical studies.

Lysine methyltransferase inhibitors: where we are now.

Feoli, Alessandra
Writing – Original Draft Preparation
;
Viviano, Monica
Writing – Original Draft Preparation
;
Cipriano, Alessandra
Writing – Original Draft Preparation
;
Milite, Ciro
Writing – Original Draft Preparation
;
Castellano, Sabrina
Writing – Review & Editing
;
Sbardella, Gianluca
Writing – Review & Editing
2022-01-01

Abstract

Protein lysine methyltransferases constitute a large family of epigenetic writers which catalyse the transfer of a methyl group from the cofactor S-adenosyl-L-methionine to histone and non-histone specific substrates. Alterations in the expression and activity of these proteins have been linked to the insurgence and progress of several diseases, including cancer, neurological disorders, and growing defects, hence they represent interesting targets for new therapeutical approaches. Over the past two decades, the identification of modulators of lysine methyltransferases has increased tremendously, clarifying the role of these proteins in different physio-pathological states. The aim of this review is to furnish an updated outlook about the protein lysine methyltransferases disclosed modulators, reporting their potency, the mechanism of action and their eventual use in clinical and preclinical studies.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11386/4774026
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact